Cipla Limited (NSE:CIPLA) reported unaudited consolidated financial results for the quarter ended 30 June 2026 on 23 July 2026. The company's net profit attributable to owners of the parent stood at Rs 789.05 crore for Q1 FY27, declining 39% year-on-year from Rs 1,297.62 crore in Q1 FY26. Consolidated revenue from operations increased 2.4% to Rs 7,119.28 crore from Rs 6,957.47 crore in the corresponding quarter last year.
Key Highlights
- Consolidated net profit for Q1 FY27 was Rs 789.05 crore, representing a 39% decline compared to Rs 1,297.62 crore in Q1 FY26, as reported to owners of the parent.
- Consolidated revenue from operations rose 2.4% year-on-year to Rs 7,119.28 crore in Q1 FY27 from Rs 6,957.47 crore in the same quarter previous year.
- Total expenses increased to Rs 6,248.25 crore in Q1 FY27 from Rs 5,446.10 crore in Q1 FY26, representing a 14.7% increase driven by higher employee benefit expenses and other operating costs.
- Employee benefits expense increased to Rs 1,497.41 crore from Rs 1,312.30 crore year-on-year, reflecting wage impact from the new labour codes effective 21 November 2025.
- Earnings per share on a basic basis stood at Rs 9.77 (not annualised) for Q1 FY27 compared to Rs 16.07 (not annualised) for Q1 FY26, a decline of 39%.
- The Board approved unaudited standalone and consolidated financial results pursuant to Regulation 33 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.
- The company holds pending litigation with the National Pharmaceutical Pricing Authority regarding alleged drug pricing overcharges dating back to 1998, with cumulative demands of Rs 2,011 crore under review.
About the Company
Cipla Limited (NSE:CIPLA, BSE:500087) is a pharmaceutical company headquartered in Mumbai, registered at Cipla House, Peninsula Business Park, Lower Parel. The company manufactures and sells pharmaceutical products across therapeutic categories. Cipla operates manufacturing facilities across India and serves domestic and international markets with a range of branded and generic medications. The company's operations include formulations, bulk actives, and contract research services. Cipla is listed on the National Stock Exchange of India Limited, Bombay Stock Exchange Limited, and the Societe de la Bourse de Luxembourg. The company's financial statements are prepared under Indian Accounting Standards as prescribed under the Companies Act, 2013.
Announcement in Detail
The Board of Directors of Cipla Limited, at its meeting held on 23 July 2026, approved the unaudited financial results (standalone and consolidated) for the quarter ended 30 June 2026, submitted pursuant to Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The Board also approved a limited review report issued by B S R & Co. LLP, the company's statutory auditors, covering both standalone and consolidated financial statements.
Consolidated revenue from operations for Q1 FY27 was Rs 7,119.28 crore, comprising Rs 7,077.02 crore from product sales and Rs 42.26 crore from other operating revenue. This represented a 2.4% increase from Rs 6,957.47 crore in Q1 FY26. Consolidated total income, including other income of Rs 210.90 crore, stood at Rs 7,330.18 crore. Total expenses for the quarter reached Rs 6,248.25 crore, an increase of Rs 802.15 crore or 14.7% year-on-year from Rs 5,446.10 crore in the prior-year quarter.
Profit before tax and share of profit from associates was Rs 1,081.93 crore for Q1 FY27, compared to Rs 1,769.93 crore in Q1 FY26. After tax expense of Rs 294.83 crore (net) and a loss of Rs 1.55 crore from associates, consolidated net profit for the period was Rs 785.55 crore. Profit attributable to owners of the parent was Rs 789.05 crore. Basic and diluted earnings per share (face value Rs 2 each) were Rs 9.77 and Rs 9.76, respectively, both not annualised. Paid-up equity share capital increased to Rs 161.57 crore during the quarter following allotment of 54,903 equity shares under the ESOS 2013-A scheme and 7,782 equity shares under the Cipla ESAR Scheme 2021.
Impact on Investors
Investors will note a significant decline in quarterly profitability despite modest revenue growth. The 39% year-on-year drop in net profit attributable to the parent reflects substantial cost pressures. The primary driver of the profit decline was a 14.7% increase in total expenses. Employee benefits expense rose 14.1% year-on-year to Rs 1,497.41 crore, largely attributable to the implementation of the New Labour Codes effective 21 November 2025. The company recognised an exceptional item of Rs 275.91 crore in the financial year ended 31 March 2026, relating to incremental gratuity and leave liabilities arising from the revised definition of "wages" under the new labour framework. Additionally, other expenses increased from Rs 1,696.32 crore to Rs 1,762.39 crore, though depreciation and amortisation decreased from Rs 252.72 crore to Rs 304.24 crore.
The filing indicates that margin compression is a key concern for the quarter. While revenue growth of 2.4% was modest, the inability to offset cost increases has resulted in substantial profit erosion. Investors should note that the company carries material contingent liabilities related to ongoing litigation with the National Pharmaceutical Pricing Authority. The company has disclosed demand notices totalling Rs 2,011 crore (comprising principal of Rs 863 crore and interest of Rs 1,148 crore) related to alleged drug pricing overcharges. Although the company has been legally advised to expect a favourable outcome and has not provided for these amounts, the litigation remains pending before the Supreme Court, and any adverse outcome could materially impact future financial results and cash flows. Additionally, employee costs may remain elevated in subsequent quarters due to the permanent impact of new labour legislation on wage definitions.
Sector / Market Context
The Indian pharmaceutical industry operates under a complex regulatory environment encompassing price controls, manufacturing standards, and employment regulations. The National Pharmaceutical Pricing Authority enforces price ceilings on scheduled drugs under the Drugs (Prices Control) Orders framework, which has been a source of regulatory disputes for multiple companies. The implementation of the New Labour Codes on 21 November 2025 has introduced significant changes to labour cost structures across industries, including pharmaceuticals. The revised definition of "wages" under the new codes has expanded the cost base for gratuity and leave calculations, affecting personnel expense lines for employers with large workforces. For Cipla, the incremental gratuity and leave liability of Rs 275.91 crore recognised in FY26 reflects the quantum of impact from this legislative change on a single company with substantial employment across multiple locations. The domestic pharmaceutical sector continues to serve both domestic consumption under price-controlled frameworks and export markets where pricing is market-driven, creating operational complexity across geographies.